Atopic dermatitis, also known as eczema, is a chronic itchy skin disease that affects over 20% of infants and young children in industrialized nations and may persist into adulthood for up to 50% of these cases, making it one of the most common skin diseases in the US and other developed countries.
Scientists at NIAID have developed a method of treating or preventing atopic dermatitis via the topical application of selected probiotic strains of gram-negative Roseomonas mucosa bacteria.This approach avoids the exhausting treatment demands of standard therapies and has been shown to be beneficial in a pre-clinical mouse model of atopic dermatitis.
Potential Commercial Applications:
• Treatment of eczema
Competitive Advantages:
• May be formulated as a cream or an ointment
• Corticosteroid-free
• Animal data available
Publications:
Myles IA, et al. Transplantation of human skin microbiota in models of atopic dermatitis. JCI Insight, 2016, Jul 7; 1(10). [PMID 27478874]
https://insight.jci.org/articles/view/86955
Intellectual Property: US Patent Application No. 62/324,762 filed 04/19/2016 (HHS Reference No. E-099-2016/0)
Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of Roseomonas species to treat eczematous (atopic dermatitis) skin disease.
Contact: Dr. David Yang, 240-627-3413; polung.yang@nih.gov.